Intravenous immunoglobulin (IVIg) has been evaluated as an adjunctive therapy for neonatal sepsis with modest clinical success despite strong biological plausibility. Multiple factors contribute to this outcome, but perhaps none greater than the limited immune system function in newborns, especially in the very premature neonates. For very premature neonates (<30 weeks gestational age), understanding the effects of IVIg on specific immature immune system functions is particularly relevant given their preponderance to develop sepsis and therefore potentially benefit from IVIg-mediated immunoenhancement. Here, we review the available evidence for enhanced immune function after IVIg administration in very premature neonates and highlight areas for future research.
Introduction
Clinical trials examining the potential benefit of intravenous immunoglobulin (IVIg), aimed at reducing the incidence and mortality of infection in neonates, began over 15 years ago. 1 Infusion of IVIg increases the typically low levels of serum immunoglobulin in preterm neonates and is postulated to lead to improved immune function that, in turn, leads to improved clinical outcome. IVIg administration has been generally well tolerated in neonates with very mild side effects, as compared with placebo, and carries minimal infectious risk due to processing that inactivates contaminating pathogens. 2, 3 Very premature neonates have the highest risk of developing a serious bacterial infection compared with more mature neonates. 4 They are the group most likely to receive and potentially benefit from effective adjuvant sepsis treatments and preventative measures. A reduction in the incidence and impact of sepsis in very premature neonates is important, especially in light of the devastating sequelae associated with neonatal infection. 5, 6 Intravenous immunoglobulin administration in neonates has been aimed at treatment of sepsis and prophylaxis to reduce the incidence of sepsis. Regarding the use of IVIg as a treatment for sepsis, a Cochrane meta-analysis showed a reduction in mortality of neonates treated with IVIg for what were subsequently proven infections (RR 0.55 (95% CI, 0.31-0.98)). 7 However, review of the included studies that showed a survival benefit (n ¼ 129, total neonates) revealed inclusion of few very premature neonates (only 15% were <30 weeks and 7.5% were <28 weeks of gestational age). Recently, a large (B5000 neonates), international, placebocontrolled, double-blind, randomized clinical trial has been undertaken to again examine the benefit of polyclonal IVIg treatment for proven or suspected sepsis in neonates. 8 However, wide entry criteria allow inclusion of neonates of all gestational and post-natal ages with suspected or proven infection. Although randomization is stratified by gender, gestational age (GA) and birth weight, the subgroup sample sizes may leave the questions of clinical efficacy for early-and late-onset sepsis in various GA groups unanswered, as seen with other important large enrollment neonatal trials. 9 Immunoglobulin preparations directed at prophylaxis against common neonatal pathogens have undergone examination for clinical efficacy. A Cochrane meta-analysis that included nearly 4000 preterm (<37 weeks) or low birth weight (<2500 g) neonates showed a very modest reduction in the development of sepsis after IVIg prophylaxis in preterm neonates (RR 0.85 (95% CI, 0.74-0.98), number needed to treat ¼ 33 to prevent 1 episode of sepsis). 10 However, a large (n ¼ 2416 neonates), prospective, multicenter, two-phase controlled trial specifically evaluated the effects of IVIg prophylaxis in very low birth weight (VLBW) neonates (<1500 g), with an average GA of 28 weeks, and found no significant reduction in nosocomial sepsis. 1 A meta-analysis of recent trials examining the prophylactic effects of immunoglobulin (INH A-21 and Altastaph studies) on the development of nosocomial sepsis caused by specific (Staphylococcus) organisms in over 2700 VLBWs showed no difference from placebo for either preparation. 11 A new humanized mouse chimeric monoclonal antibody directed against Staphyloccocal lipotechoic acid (a major component of the bacterial cell wall) as a means of sepsis prophylaxis is currently in phase II trials. 12 Multiple reasons have been suggested for the limited efficacy of IVIg for prevention or treatment of neonatal sepsis and include limitations in study design, insufficient dosing, variation in pathogens, low levels of neonatal pathogen-specific antibodies and use of non-IgM-enriched products. 9 An additional explanation for the lack of efficacy of IVIg may be the immature immune function of very premature neonates. Different aspects of immune immaturity among very premature neonates may impact how IVIg works to prevent or treat sepsis.
Immunoglobulin is central to multiple interconnected mechanisms of the immune system that allow a host to defend against microbial infection. 13 However, immunocompetence requires the presence and concerted effort of multiple immune elements, including immunoglobulin, complement and functional cytotoxic phagocytes. Available evidence indicates that much of this complex system does not function in very premature neonates in the same manner as in more mature neonates, children or adults. [14] [15] [16] [17] [18] In neonates, administration of IVIg may improve immune responses by binding to cell surface receptors, provision of opsonophagocytic activity, including activation of complement, promotion of antibody-dependent cytotoxicity and improvement of neutrophil (PMN, polymorphonuclear leukocyte) respiratory burst. 7, 19 Additional effects of IVIg may include a reduction of an overexuberant inflammatory reaction that may accompany severe sepsis or septic shock. Anti-inflammatory mechanisms attributed to IVIg include binding of endotoxin, reduction of proinflammatory cytokine production and excessive complement activation, regulation of CD8-mediated suppressor or cytotoxic T-cell function, reduction of inflammation and PMNs in inflamed tissues 20 and resolution of neutropenia. 8 Diverse anti-inflammatory immunomodulatory changes have been associated with IVIg in adults and are believed to be the mechanisms behind the benefit seen when administered to those with inappropriate immune system activation. 21 Therefore, reductions in inflammatory capacity and cellular function, as a result of immunomodulation due to IVIg administration, has the potential to further increase the risk for fulminant progression by rendering the already functionally immunocompromised very premature neonate even less able to respond to microbial invasion. These risks are particularly concerning, given the lack of clear and substantial benefit of IVIg administration for either prophylaxis or treatment of sepsis in this population.
Despite the fact that valuable improvements in immune function directly related to IVIg administration have been substantiated in more mature neonates, studies of immunomodulation of very premature neonate immune functions after IVIg administration are scarce and have not shown the expected functional improvements. When studies evaluating the effects of IVIg included preterm babies, 'preterm' was often defined as 30-36 weeks completed gestation. Evaluation of function in neonates with GA <30 weeks were often not included and, when included, were usually not evaluated as a separate group (Table 1) . Extrapolating the beneficial effects related to IVIg in more mature populations to very premature neonates may be inappropriate and should be done with caution.
Because IVIg has thus far failed to produce the clear clinical benefits hoped for among very premature neonates, close scrutiny of the differences between the immune systems of these infants, their term counterparts, older children and adults may reveal reasons for the limited value of IVIg prophylaxis and therapy in the very premature neonates while pointing toward opportunities to improve the state of the art.
This review has been organized beginning with different questions about the putative benefits of IVIg 7, 19 followed by a discussion of the available data in very premature neonates. The clinical trials performed to date have not been conducted in such a manner as to prove or disprove specific mechanisms through which IVIg benefits or fails to benefit the VLBW neonate in preventing or attenuating sepsis. However, some limited data are available to consider how IVIg may or may not interact with the immune system of this patient group. We have focused this review primarily on these data, and highlighted essential areas for future research to fill the significant gaps in knowledge regarding the constitution and function of the very premature neonatal immune system.
IVIg-mediated immunological alterations in very premature neonates Does IVIg improve opsonization and phagocytosis in very premature neonates?
Binding of immunoglobulin to cell surface receptors improves clearing of bacteria by functional monocytes, macrophages and PMNs
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( Figure 1 ). Prevention or treatment of sepsis through the presence of pathogen-specific antibodies has the potential for a significant reduction in the attack rate, assuming that binding of immunoglobulin leads to the right series of events that remove the bacteria from circulation. Important cell surface receptors responsible for binding immunoglobulin include F C g-receptor I (FcgRI (CD64)), FcgRII (CD32) and FcgRIII (CD16). However, PMN surface expression of FcgRII (CD32) and III (CD16), necessary for group B Streptococcus (GBS) recognition, 23 may be profoundly decreased at birth in very premature neonates as compared with more mature neonates and adult controls. 24, 25 Expression of these receptors may improve over the first 2-3 post-natal weeks in healthy, unstressed very premature neonates. However, Carr and Davies 26 showed in 27 babies born between 24 and 32 weeks (mean age, 27 weeks) that stress (respiratory distress syndrome or sepsis) was associated with a reduction of 42 ELBWs, examined at birth and after average of 29 (14-56) days (n ¼ 14)
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kPMN CD16 in well-preterm neonates compared with term neonates or adults with further k noted in stressed preterm neonates that remained k for at least up to 3 weeks of age. CD32 equivalent to adults in both well and stressed preterm neonates PMN FcgRIII (CD16) surface expression that persisted over at least the first 3 weeks of post-natal life. In contrast, PMN surface expression of FcgRI (CD64) is significantly elevated in very premature neonates at birth versus birth levels in term neonates and at baseline in adults, but equilibrates to levels seen in growing term neonates within the first month of life. 25 Unlike FcgRII (CD32) and FcgRIII (CD16), significant upregulation (fivefold) of FcgRI (CD64) surface expression occurs on PMNs during infection in very premature neonates. As a result, FcgRI (CD64) has been proposed as an adjunct test for diagnosis of sepsis. 27 Monocytes from term neonates have been shown to express similar levels of FcgRI (CD64), as well as significantly higher levels of FcgRII (CD32) 28 and III (CD16) 22 compared with adults, but the expression levels and relative function of macrophage FcgR are not specifically known in very premature neonates, leaving a key arm of innate and adaptive immunity incompletely characterized in these patients. In summary, FcgRII (CD32) and III (CD16) expression can be significantly lower in PMNs from very premature neonates as compared with term neonates and adults, and expression rises toward adult levels over the first post-natal weeks. In contrast, elevated PMN FcgRI (CD64) surface expression at birth in very premature neonates decreases to levels seen in growing term neonates within the first month of life and is upregulated with infection.
Increased surface expression of FcgRI (CD64) is associated with enhanced PMN phagocytic function in adults. 29 On the basis of the observations that PMNs from very premature neonates express increased FcgRI (CD64) and that these infants have profound transient hypogammaglobulinemia (<100 mg per 100 ml), 17 the premise for using IVIg to raise plasma immunoglobulin levels and improve opsonophagocytosis is biologically rational. Indeed, opsonophagocytic activity is improved after the addition of IVIg to serum from term neonates, 30 but the effect may be variable based on concentrations of neonatal pathogen-specific immunoglobulin. 31 The effect is largely dependent on the presence and functional activity of complement. 32 Furthermore, opsonization has little effect in the absence of competent cellular function that is required to engulf and kill the pathogens after effective opsonization. Preterm (28-34 weeks GA) neonates exhibit decreased PMN opsonic capacity, phagocytosis and respiratory burst compared with term neonates and adults, 15 and this may be worse in very premature neonates. 33, 34 Improvements in cellular function (phagocytic function and H 2 O 2 production) following IVIg administration were shown in a cohort of nine preterm neonates (average GA, 33 weeks). 35 Unlike the positive results seen in term and late-preterm neonates after IVIg administration, ex vivo phagocytosis of GBS by very premature neonate PMNs in serum pooled from very premature neonates was not improved after the addition of IVIg or IgM-enriched IVIg preparations with a high concentration of GBS-specific antibodies. 34 Preterm neonates have reduced specific serum complement components as well as decreased function of both the alternative and classical pathways, as compared with more mature neonates. 16 Studies in preterm neonates have shown the importance of complement activation for effective opsonophagocytosis. 32, [36] [37] [38] PMNs from premature neonates (mean age at birth, 31 weeks) showed that FcgRIII (CD16) has a major role in opsonophagocytosis of coagulase-negative Staphylococcus (CoNS), the predominant pathogen associated with late-onset sepsis in the very premature neonate, 39 but again complement is required. 36 As discussed previously, FcgRIII (CD16) expression on very premature neonate PMNs is profoundly decreased at birth, remains low over the first post-natal weeks and is decreased further with clinical stress. 26 Krediet et al. 40 studied the relationship between PMN responses to CoNS and specific anti-CoNS antibody levels in a cohort of 60 premature (26-32 weeks) neonates (20 with late-onset CoNS bacteremia and 40 age-matched controls) and found that levels (high or low) of specific immunoglobulin did not improve opsonic responses. Therefore, even in the presence of adequate pathogen-specific antibody and deposition of antibody on the bacterial surface, the decreased FcgRIII (CD16) receptor expression on the effector cells and the low serum complement levels seen in preterm neonates may limit opsonophagocytosis and the clinical efficacy of IVIg in preventing or treating CoNS infection. 41 In conclusion, despite successful immunoglobulin binding to target bacteria and increased PMN FcgRI (CD64) expression, bacterial clearance through effective PMN phagocytosis is limited in very premature neonates and seems to be complement dependent.
Complement can be activated by IVIg and participates in both opsonization of pathogens and direct microbicidal activity. In serum from premature neonates (mean GA, 33 weeks), IVIg activated both complement pathways (alternative > classical) to deposit C3 on non-encapsulated bacterial surfaces. 37 However, the majority of pathogens associated with neonatal sepsis (for example, CoNS, S. aureus, Enterococcus sp, GBS, Escherichia coli, Enterobacter sp, Klebsiella sp, Serratia sp, Pseudomonas sp) 39 predominantly exhibit some form of encapsulation. No increase in the C3 deposition on the bacteria was seen in term neonates after IVIg infusion for treatment of sepsis, although IgG deposition on the bacterial surface was increased to levels equal to or greater than that seen in adult sera. 42 Complement deposition on S. pneumoniae was equivalent in term and adult serum, but significantly lower in serum from preterm neonates (28-33 weeks). 32 A single study used pooled serum from two healthy preterm neonates with birth weights <850 g and found that addition of IVIg increased C3 deposition on CoNS. 43 Future studies to provide greater resolution of the functional deficits in complement activation and to show how these deficiencies respond to IVIg in premature neonates will be essential to understand the mechanisms behind the benefits or lack of benefits of IVIg therapy. Evaluation of the effects on complement activation after the addition of IVIg in more premature neonates (that is, <28 weeks) and on a wider panel of additional pathogenic bacteria has not been evaluated. Does IVIg promote antibody-dependent cytotoxicity in very premature neonates? Antibody-dependent cellular cytotoxicity (ADCC) is important for pathogen clearance, particularly for viruses including human immunodeficiency virus and Herpes simplex virus. In addition, clearance of intracellular bacteria such as Listeria sp or Mycoplasma sp may depend on this mechanism. ADCC is primarily mediated by natural killer cells and monocytes, and can also be carried out by PMNs. Natural killer cells from term neonates exhibit decreased ADCC in the presence of adequate and specific antibodies, 44 although cytotoxicity is improved with labor and vaginal delivery compared with delivery by C-section. 45 PMN-mediated ADCC in term neonates was equivalent to that seen in adults when the target was antibody coated. [46] [47] [48] Examinations of peripheral blood mononuclear cell ADCC have shown depressed function (50% of adult) in term [49] [50] [51] [52] and preterm neonates (<30 weeks and 30-35 weeks, respectively) 53 in the presence of adequate pathogen-specific antibody. Examination of natural killer and PMN-mediated ADCC in very premature neonates has not been performed.
Does IVIg improve PMN function and sepsis-associated neutropenia in very premature neonates?
Respiratory burst (historically measured by chemiluminescence) is a natural product of metabolic oxygenation activity and has been used to describe PMN activation. Very premature neonates exhibit a diminished PMN respiratory burst, as compared with more mature neonates. 33 PMN respiratory burst is suppressed during sepsis, particularly in the preterm neonate, and may contribute to poor microbicidal activity. [54] [55] [56] Evaluation of very premature neonate PMN respiratory burst after IVIg administration has not been performed. Improvement in PMN phagocytic function after IVIg administration has been shown in term 30 and preterm (average GA, 33ks) neonates, 35 but was not improved in PMN from very premature neonates. 34 Investigations of the effects of IVIg treatment for sepsis in preclinical models that mirrored term neonate immune systems revealed a more rapid release of PMNs from the storage pool with improved accumulation at the site of the bacterial inoculation, which was associated with improved survival as compared with controls. 57, 58 IVIg administration to a cohort of neonates (mean GA, 33 weeks) with early-onset sepsis and neutropenia resulted in improvement of PMN counts within 24 h of treatment, which was not seen in the control group. 59 The effect of IVIg on neutropenia and recruitment to the site of infection has not been evaluated in very premature neonates.
Are there other benefits of IVIg administration for very premature neonates? Unlike those effects that require the concerted actions of other functional immune elements, benefits of IVIg infusion that do not will likely remain intact in the very premature neonate. For example, antibodies against endotoxin and cytokines have been shown in IVIg. [60] [61] [62] A reduction in these substances may have a positive effect and improve clinical outcomes. An antiinflammatory benefit (reduced IL-6 production) was shown by co-incubation of IgM and lipopolysaccharide (endotoxin) ex vivo in cord blood from well-term and preterm neonates (n ¼ 10, average, 30 weeks, 23-34 weeks). 63 Intravenous immunoglobulin may also have a role in the attenuation of exuberant inflammation that might occur during severe sepsis. IVIg has been used successfully as an antiinflammatory treatment in older populations (children, adults) with inappropriate immune system activation. Investigations into the mechanisms responsible for the reduction in inflammation associated with IVIg have been performed in immunologically mature populations. 21 Augmentation of the cytokine network (decreased proinflammatory and increased anti-inflammatory cytokines), inhibition of cellular activation, differentiation and effector function (antigen presenting cells, B cells and T cells), reduction in complement activation and increased apoptosis of PMNs have all been shown after IVIg administration. 13, 64 These effects would provide further biological plausibility for the benefit of IVIg in suppression of overactivated inflammatory cascades in an otherwise competent immune system. However, the immunoregulatory response to IVIg requires specific intact and responsive cellular receptors such as FcgRII, a known negative regulator of inflammation and also downregulated in the leukocytes of very premature neonates. 25 Furthermore, immunosuppression of an already immuno-immature host, such as the very premature neonate, must be viewed with caution. These immunomodulatory effects could be potentially catastrophic if they occurred in the septic and already relatively immunocompromised very preterm neonate. However, in certain clinical situations that may be associated with excessive inflammatory activation, such as that seen during neonatal septic shock, IVIg-mediated reduction of the systemic inflammatory response may lead to improved outcomes. Assessment of serum inflammatory markers (cytokines, acute phase reactants, etc) before and after IVIg treatment in septic neonates has not been performed. Compared with placebo, no reduction in inflammationrelated morbidity (patent ductus arteriosus, chronic lung disease), length of hospital stay or death was shown after administration of prophylactic IVIg to over 1200 VLBW neonates. 1 However, a small but significant increase in necrotizing enterocolitis (Bell's stage 2 or greater) was noted in those who received IVIg (12%) over placebo (8%). No statistically significant reduction or increase in patent ductus arteriosus, necrotizing enterocolitis (any stage), chronic lung disease, periventricular leukomalacia, retinopathy of prematurity (any stage), bacterial infection (Staphyloccocus or other bacteria) or death was noted in a meta-analyses of anti-staphylococcal immunoglobulin prophylaxis studies in >2700 VLBW neonates. 11 The potential of IVIg as an anti-inflammatory agent has prompted its consideration as a therapy to prevent brain injury in preterm neonates. 65 Well-designed studies in the future are necessary to delineate the potential beneficial effects as well as the potential to harm after inflammatory modulation by IVIg in very premature neonates.
Discussion
Multiple studies have evaluated the efficacy of IVIg as prophylaxis or treatment for infection in neonates. A meta-analysis showed a reduction in mortality for neonates with subsequently proven infection treated with IVIg, 7 but studies reporting benefit included few very premature neonates. A second meta-analysis showed a very modest reduction in the development of late-onset sepsis following IVIg prophylaxis in preterm neonates. 10 IVIg preparations aimed at reducing the incidence of infection with specific pathogens 66 seem to be safe in the study populations tested, 67 but larger studies have not shown efficacy. 68, 69 At present, the available data are incomplete or do not support the suggested immunoenhancements attributed to IVIg in very premature neonates. Evaluation of IVIg-mediated effects on immune function should be performed using homogenous (exclusively very premature immune components) ex vivo and in vitro systems. These studies are desperately needed and will not only greatly contribute to our understanding of the potential for immunoenhancement in the very premature neonate but also more accurately represent the effects of treatment in vivo. In addition, future studies must distinguish between the mechanisms through which IVIg may act as a prophylactic agent and those through which it may act as a treatment for ensuing sepsis. On the basis of the limited data examining pertinent very premature neonate immune function and the subsequent response following IVIg treatment in vitro, ex vivo and in vivo, it is seems unlikely that IVIg alone will produce the desired benefits. Combination therapies (that is, IVIg and colony stimulating factor; IVIg, complement containing blood product and colony stimulating factor) have been suggested 70 and may yield significant immune improvements, but it should also be studied in homogenous systems. Considerable future research will be necessary to improve our understanding of immune system development in very premature neonates and identify points in the immune response in which more sophisticated interventions may make a difference.
Conclusion
Very premature neonates exhibit the greatest incidence of sepsis among neonates and have the most to gain from successful immunomodulation strategies. IVIg prophylaxis in preterm neonates has shown a very modest benefit in prevention of sepsis. Studies documenting benefit that are included in the meta-analysis of IVIg treatment for neonatal sepsis included only a few very premature neonates. Many of the immunological modulations ascribed to IVIg are not present or have not been examined in very premature neonates. Ex vivo evaluation of the immunological effects of IVIg administration should use homogenous very premature immunological systems in order to most accurately replicate the in vivo environment. These studies are particularly relevant and necessary given the continued interest and potential of IVIg as treatment or prophylaxis for infection.
